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Abstract.  The ability to penetrate the dermal base- 
ment membrane and subsequently proliferate in the 
underlying mesenchyme is one of the key steps in 
malignant progression of human melanomas. We pre- 
viously undertook studies aimed at assessing how 
normal dermal fibroblasts (one of the main cellular 
components of mesenchyme) may affect the growth of 
human melanoma cells and facilitate the overgrowth of 
malignant subpopulations (Comil, I., D. Theodorescu, 
S. Man, M.  Herlyn, J. Jambrosic, and R.  S. Kerbel. 
1991. Proc.  Natl.  Acad.  Sci.  USA.  88:6028-6032). 
We found that melanoma cell lines from early-stage 
(metastatically incompetent) lesions were growth in- 
hibited whereas those from advanced-stage (metastati- 
cally competent) lesions were stimulated under the 
same conditions by co-culture with fibroblasts; condi- 
tioned medium from such cells gave the same result. 
Subsequent studies using biochemical purification and 
neutralizing antibodies revealed the inhibitory activity 
to be identical to interleukin-6 (IL-6). We now report 
that addition of purified recombinant human IL-6 re- 
suited in a growth inhibition in vitro by G1/G0 arrest 
of early, but not advanced stage melanoma cells. De- 
spite this alteration in response there was no signifi- 
cant difference in melanoma cell lines of varying malig- 
nancy in respect to their expression of genes encoding 
the IL-6 receptor, or gp130, the IL-6 signal transducer. 
Scatchard analysis also revealed similar [125I]IL-6 bind- 
hag activities in both IL-6 sensitive and resistant groups. 
However, studies of IL-6 production indicated that five 
out of eight IL-6 melanoma cell lines known to be re- 
sistant to exogenous IL-6-mediated growth inhibition 
constitutively expressed mRNA for IL-6; they also se- 
creted bioactive IL-6 into culture medium. To assess 
the possible role of this endogenous IL-6 in melanoma 
cell growth, antisense oligonucleotides to the IL-6 
gene were added to cultures of melanoma cells. This 
resulted in a significant growth inhibition only in cell 
lines that produced endogenous IL-6.  In contrast, neu- 
tralizing antibodies to IL-6 were ineffective in causing 
such growth inhibition. This indicates that endogenous 
IL-6 may behave as a growth stimulator by an intracel- 
lular ("private")  autocrine mechanism. Thus, a single 
cytokine, IL-6, can switch from behaving as a paracrine 
growth inhibitor to an autocrine growth stimulator 
within the same cell lineage during malignant tumor 
progression. Such a switch may contribute to the growth 
advantage of metastatically competent melanoma cells 
at the primary or distant organ sites and thereby facili- 
tate progression of disease. 
E of the  mechanisms by  which cancer cells  are 
ought to acquire a growth advantage is through the 
"autocrine" production of mitogenic growth factors 
(2, 48). This refers to the process whereby cancer cells, or 
their dysplastic cellular  precursors, begin to express a growth 
factor (or receptor for the growth factor) which their normal 
cellular counterpart does not normally express. The recep- 
tors may be cell surface associated or expressed intracellu- 
larly, thereby creating "public or "private" autocrine loops, 
respectively (4). 
In the case of solid  tumors,  whether carcinomas, sar- 
comas, or tumors of neuroectodermal origin (e.g., brain 
tumors, malignant melanoma), the nature of many of these 
autocrine growth factors  involved in their growth is  well 
known (2). They include, for example, members of the FGF 
family  such as basic  FGF  CoFGF), PDGF,  transforming 
growth  factor-c~ (TGF-c~),  1  EGF, and  the  insulin-like 
growth  factors,  IGF-I  and IGF-H.  Conspicuously  absent 
from this  list  are members of the hemopoietic family of 
cytokines and growth factors (13, 35). These include the in- 
terleukins fILs), colony stimulating factors (CSFs), erythro- 
poietin and stem cell factor (SCF).  Not surprisingly, these 
factors have been studied predominantly as paracrine or au- 
tocrine regulators of the growth of leukemias and lympho- 
mas (2, 13). However, there is a small (but growing) litera- 
1. Abbreviations used in this paper: CM, conditioned media; IL, interleu- 
kin; rhIL-6,  recombinant human IL-6; TGF, transforming growth factor. 
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factor family may also help regulate the growth of solid 
tumors directly, especially in a paracrine manner (5, 9,  10, 
39, 45). Prominent among these factors may be interleukin-6 
(IL-6). 
IL-6 is produced by a variety of cells including fibroblasts, 
endothelial cells,  keratinocytes (all of which make this a 
potentially interesting cytokine for skin cancers, including 
melanoma), T  and B  lymphocytes and monocytes/macro- 
phages (18, 27, 57).  It is thought to be a major molecular 
mediator of inflammatory conditions, acute phase protein 
synthesis in the liver, and various immunological reactions 
(27). With respect to hematologic cancers it has been shown, 
for example, to behave as an autocrine growth factor for 
some lymphomas and human multiple myelomas in culture 
(24, 29, 40, 65). 
We recently uncovered evidence to show IL-6 can affect 
the growth properties of human melanomas differentially as 
a function of tumor progression (30).  Thus, the growth of 
cell lines established from early-stage benign (curable) pri- 
mary melanomas was inhibited by co-culture with normal 
dermal fibroblast or conditioned media from such cells (8). 
In  contrast,  cell  lines  established  from  more  advanced 
(malignant) primary melanomas, or metastases, were stimu- 
lated under the same conditions (8). The activity responsible 
for the growth inhibition of early-stage melanoma cells was 
subsequently identified as being IL-6 (30); the nature of the 
stimulator has  not yet been determined.  Consistent with 
these conclusions was the finding that addition of nanogram 
amounts of recombinant human IL-6 to early-stage mela- 
noma  cells  was  profoundly  inhibitory  to  their  growth 
whereas  cells  from more advanced cell lines were com- 
pletely resistant to this inhibition (30). 
The purpose of the present studies was to investigate the 
possible reasons for the transition in responsiveness to IL-6 
during melanoma progression. Such a transition could pro- 
vide malignant (i.e.,  metastatically competent) melanoma 
cells with a growth advantage, helping them to acquire the 
ability to proliferate in the foreign environment of  the dermal 
mesenchyme (6), and thus achieve 'clonal dominance' (25). 
We examined the IL-6 receptor status, and IL-6 production 
itself, among different melanoma cell lines obtained from 
different stages of disease progression. We found evidence 
that IL-6 is produced by >50%  of the advanced stage cell 
lines, and surprisingly, that it can function as an intracellular 
autocrine growth factor in such cells. Thus a single growth 
factor can change from functioning as a (paracrine) inhibitor 
to an autocrine stimulator within the same cell lineage dur- 
ing the multi-step process of malignant tumor progression. 
Materials and Methods 
Cell Culture and Growth  Assay 
The human melanoma cell lines used in these studies are the same as de- 
scribed previously (8,  14,  15, 30). The cell lines in RPMI  1640 medium 
containing 5% FBS (8, 30). With the exception of SKMEL28 and MeWo, 
the cell lines were established from different lesional stages  of disease 
progression in the laboratory of Dr. M. Herlyn (Wistar Institute, Philadel- 
phia, PA) (14, 15).  Some were derived from early-stage nonmalignant pri- 
mary tumors, i.e., from radial growth phase (RGP) or early ("thin") vertical 
growth phase (Vt3P) primary melanomas. Patients were cured by surgical 
removal of these lesions. Other cell lines were authentic "malignant" (i.e., 
metastatically competent) melanomas. They were derived from either ad- 
vanced local VGP primaries where there was evidence that the patient had 
distant metastases at the time the primary lesion was removed, or from dis- 
tant metastases (14, 15). In experiments designed to assess cell proliferation 
by  [3H]thymidine incorporation,  5  ￿  103 cells were plated into 96-well 
plates with or without recombinant human IL-6 (rhlL-6) (Upstate Biotech- 
nical Inc., Lake Placid, NY) in triplicate, using ExCell 300 medium (J. R. 
Scientific, Woodland, CA) and 1% FBS. Cells were cultured at 37~  for 
2  d.  50  #1  of 2.0 #Ci  [3H]thymidine  (25  Ci/mmol;  Amersham Corp., 
Arlington Heights, IL) was added to culture wells and cells incubated for 
another 4-6 h before being harvested in a Titertek Cell Harvester 530 with 
Printed Filtermat A (Pharmacia Fine Chemicals, Piscataway, NJ). Radioac- 
tivity in the harvested filters was counted in 1205 Betaplate  TM scintillation 
counter (Wallac, Gaithersburg, MD). 
Flow Cytometric DNA Analysis 
Human melanoma cells (1  ￿  106 cells) were plated overnight in 100-ram 
dishes in RPMI 1640 medium containing 5 % FBS. The culture medium was 
then changed to RPMI 1640 medium containing 2% FBS without or with 
rhIL-6 at 20 ng/ml concentration for 24 h. Ceils were harvested by trypsini- 
zation and washed three times with PBS. The cell pellets were then frozen 
and nuclei prepared as described previously (58, 59).  DNA content was 
measured in EPICS Elite flow cytometer (Coulter Electronics, Inc., Hia- 
leah, FL) using propidium iodide staining (58, 59) and the data were ana- 
lyzed with the software program provided by the supplier. 
Scatchard Analysis of lL-6 Receptors 
Determination of the affinities and sites of IL-6 binding to human melanoma 
cell lines was conducted essentially as described before by Taga et al. (51). 
Briefly,  purified carrier-free rhIL-6 (20.3 kD, purchased from R & D Sys- 
tems, Minneapolis, MN) was radio-iodinated with Bolton-Hunter reagent 
(Amersham Corp.).  [125I]IL-6 was separated from free iodine by Sephadex 
G-50 column chromatography. The specific activity of [125I]IL-6 was 4.4 
￿  1013 cprodg  as determined in a  human myelomonocytic leukemia cell 
line, called CESS (American Type Culture Collection, Rockville, MD) by 
self-displacement analysis. Incubation of [~25I]IL-6 with human melanoma 
cells (0.8-1.3  x  106) was carried out in ice (0~  for 150 rain in a final vol- 
ume of 70 #1 in RPMI  1640 medium containing 20 mM Hepes, pH 7.4, 
and 1 mg/ml BSA. Specific binding of [1251]IL-6 to human melanoma cells 
was calculated after subtracting from the total binding counts of samples 
with 250  ng of unlabeled rhIL-6 (Upstate Biotechnology Inc.)  i.e.,  the 
nonspecific binding.  Experiments  were  done in duplicate.  Data  are  ex- 
pressed by mean +  standard error of three separate experiments. 
Northern Blotting Analysis of mRNA 
Poly(A)  + RNA was prepared by use of oligo (dT) cellulose (3) from human 
melanoma cell lines that were cultured in RPMI 1640 medium containing 
5 % FBS. For Northern blot analyses, 3-6 #g of poly(A)  + RNA was size- 
fractionated in 1% formaldehyde agarose gels.  Hybridizations were con- 
ducted at 65~  overnight using 32p-labeled eDNA probes,  eDNA probes 
for human IL-6 (TaqI/BanII fragment), IL-6 receptor (FspI/EspI fragment), 
gpl30  (AccII/BamHI fragment) and human liver glyceraldehyde-3-phos- 
phate dehydrogenase (GAPDH, Psfl/XbaI fragment, American Type Cul- 
ture Collection) were radiolabeled with 32p-dCTP and Klenow fragment of 
DNA polymerase I and random hexamer primers (16,  17, 55, 62). 
B9 Cell Bioassay  for IL-6 Proliferative  Activity 
The IL-6-dependent murine B-cell hybridoma B9 cell line was used and 
cultured as described previously (1, 42). Conditioned media (CM) of human 
melanoma cell lines were collected and assayed as follows: melanoma cells 
were subcultured in 6-well plates until confluent in RPMI medium contain- 
ing 5% FBS. A total of 2.5 ml of the same medium as well as fresh medium 
was then added into the culture overnight and CM was collected (called 
'CMr) which contained 5 %  FBS.  Subsequently, cells were washed once 
with PBS and cultured in 2.5 ml of ExCell 300 medium overnight. The 
serum-free medium (called CM2) was then collected. B9 cells were plated 
and cultured in 96-well plates at 104 cells per well, with or without CM ob- 
tained from melanoma cell cultures or rhlL-6 and/or anti-hlL-6 neutralizing 
antibody, at 37~  for 2 d. Cells were pulse-labeled with [3H]thymidine for 
4-6  h  before being harvested in glass fiber filters,  as  described  above. 
Stimulating units of melanoma cell CM were calculated by the concentra- 
tion of CM that doubled the [3H]thymidine uptake in B9 cells. 
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Inhibition of CeU Growth 
A 15-base antisense  oligodeoxynueleotide  (TCC~TACTGG)  that is 
specific for a sequence of the second exon of IL-6 gene was used, as de- 
scribed by others previously (29, 34, 64). The antisense and a control 15- 
met sense oligonucleotide were synthesized by Pharmacia Biotechnology 
Service Centre (Toronto, Ont.) and phosphorothioate preparations were 
made in the Department of Medical Genetics, University of Toronto. To as- 
sess the effect of antisense oligonucleotides on the growth of melanoma cell 
lines, cells were cultured in 24-weU plates (104 cells per well) with or with- 
out 10/zM of the oligonucleotides in RPMI 1640  medium containing 5% 
FBS  for 5  d.  [3Hlthymidine incorporation was conducted as described 
above with addition of oligonucleotide preparations. Cell numbers were 
counted by trypan blue exclusion in a hemocytometer. Celt number in wells 
without oligonucleotide was calculated as 100%. 
Results 
IL-6 Arrests Early-Stage Melanoma Cell Growth 
at the G1/GO Boundary of the Cell Cycle 
Previously, we had found that recombinant human IL-6 in- 
hibited the proliferation of three out of four melanoma cell 
lines that were derived from early-stage (metastatically in- 
competent) primary lesions (30). These three cell lines were 
WM35, WM902B, and WM1341B; they are grouped and re- 
ferred to in this paper as "IL-6 sensitive." The exception is 
the WM793 cell line, which is not growth inhibited by IL-6 
(but which is, by exposure to IL-1 and TNFo0. Among the 
seven  human  melanoma  cell  lines  derived  from  either 
advanced-stage primary tumors, or metastases,  none was 
growth inhibited significantly by the addition of  IL-6 into the 
culture  medium  (30).  These  are  WM1361A,  WM983A, 
WM1205,  WM9,  WM451,  MeWo,  and SKMEL28, which 
(including WM793) are referred to as the "IL-6-resistant" 
group. 
Flow cytometric DNA analysis was conducted in cell lines 
from both IL-6 sensitive and resistant groups of melanoma 
cells. As shown in Fig.  i  and Table I, addition of recom- 
binant human IL-6 into culture medium resulted in a time- 
dependent growth inhibition of WM35  cell growth as as- 
sessed by [3H]thymidine incorporation. This corresponded 
to a decrease in cell numbers in S phase, and to an increase 
in cell numbers in the G1 phase. Similar changes were also 
found in other cell lines that are sensitive to IL-6 induced 
growth inhibition (Table I). The results suggest that IL-6 in- 
duced growth inhibition of early-stage melanoma is medi- 
ated by arrest in the G1/G0 boundary of the cell cycle. As ex- 
pected, changes of cell ratio in G1 and S phase upon addition 
of IL-6 were not observed in IL-6 resistant, advanced-stage, 
malignant melanoma cell lines. 
Evaluation of  lL-6 Receptor Status in Melanoma 
Cell Lines 
Northern blotting analysis revealed similar levels of IL-6 re- 
ceptor gene expression in both IL-6 sensitive and IL-6 resis- 
tant cell lines (Fig. 2). However, it is known that IL-6 recep- 
tor itself does not possess signal transduction function and 
that IL-6 action is mediated through "gp130" after IL-6 binds 
to its receptor (16, 38). We therefore examined the levels of 
mRNA for gp130 but did not find any marked difference in 
gpl30 gene expression among these human melanoma cell 
lines (Fig. 2). This suggests (but does not prove) that defec- 
tive gpl30 or altered expression of gpl30, is not involved in 
200 
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Incubation time with hIL-6 (h) 
Figure L IL-6 induced time-dependent growth inhibition is by G1 
cell  cycle  growth arrest.  [3H]thymidine incorporation  (A)  of 
WM35 human melanoma cells was determined after culturing the 
cells in the absence or presence of human IL-6 (10 ng/ml) for the 
period of  time as indicated before cells were pulse labeled. Percent- 
age of cells in G1 phase (e) and S phase (o) were analyzed as de- 
scribed in Materials and Methods. Controls without IL-6 treatment 
at each time point were considered as 100%. 
the transition in responsiveness of melanoma cells to IL-6 
during disease progression. 
The function of expressed IL-6 receptors was  also as- 
sessed by analyzing [~25I]IL-6  binding to the gpS0 receptor 
by Scatchard analysis. As summarized in Table II and Fig. 
3, there was no significant difference between IL-6-sensitive 
and  IL-6-resistant  groups  in  terms  of [~25I]IL-6 binding 
affinities and binding sites per cell. The cell line 9-A6-1 used 
in this experiment was cloned from WM9 after being trans- 
fected with an IL-6 antisense expression vector. WM9 cells 
normally produce IL-6 (see below) and we wished to isolate 
variants of WM9 cells which were significantly suppressed 
in a constitutive manner for IL-6 production to test in vivo 
(our own unpublished observations). The 9-A6-1  cells are 
resistant to IL-6 mediated growth inhibition. In Scatchard 
analysis, we used the CESS cell line as a positive control and 
obtained a binding affinity and receptor number comparable 
with those published by Taga et al.  (51). 
Endogenous IL-6 Production by IL-6 Resistant 
Cell Lines 
Northern blotting analysis of poly(A)  § RNA from these hu- 
man melanoma cell lines revealed that IL-6 mRNA was de- 
Table L Cell Cycle Analysis of  Human Melanoma Cell 
Lines With or Without IL-6 Treatment* 
IL-6 added 
Percent G1  Percent G2tM  Percent S 
phase cells  phase cells  phase cells 
-  +  -  +  -  + 
WM  35  52.2  74.7  11,6  5.0  36.2  20.3 
WM 902B  67.4  87.3  13.4  8.5  19.3  4.2 
WM  1341B  74.6  83.2  0.6  3.6  24.8  13.2 
WM 75  63.1  84.4  6.3  2.0  30.6  16.5 
WM 983A  65.2  64.2  1.9  5.1  32.9  30.7 
SKMEL 28  75.3  73.3  3.5  3.5  21.3  23.2 
* 1 x  1@ cells were cultured in 100-ram dishes in RPMI 1640 medium con- 
mining 2% FBS with or without rhlL-6 at 20 ng/ml for 24 h. Nuclei prepara- 
tions were used for cell cycle analysis after propidium iodide staining. Human 
melanoma cell lines WM 35, WM 902B, WM 1341B, and WM 75 are growth 
inhibited by IL-6, but WM 983A and SKMEL 28 are not (30). 
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expression in human melanoma cell lines. 3 ttg of poly(A) + RNA 
from  each cell line was loaded into each lane before electropboresis. 
eDNA probes for IL-6 receptor, gpl30 and GAPDH used were as 
described  in Materials  and Methods. 
tectable in five out of eight cell lines that are resistant to IL-6 
growth inhibition. None of the three IL-6 sensitive cell lines 
showed evidence of endogenous IL-6 expression (Fig.  4). 
Similar IL-6 mRNA levels were found in another separate ex- 
periment. To address the question of whether these five cell 
lines-WM793,  WM1205,  WM9,  MeWo, and WM1361A- 
produce and secrete biologically active IL-6, we tested the 
CM obtained from these cell cultures in the B9 murine ceil 
bioassay. CM  from three IL-6-sensitive cell lines did not 
demonstrate significant stimulatory activity for B9 cells, as 
monitored  by  pH]thymidine  incorporation.  In  contrast, 
CM from the five IL-6-resistant cell lines containing detect- 
able levels of IL-6 mRNA were found to significantly stimu- 
late the proliferation of B9 cells in both FBS containing CM1 
(data not shown) and serum-free CM2 (Fig. 5 A). Moreover, 
the stimulatory activity on B9 ceils by conditioned medium 
could be abrogated by addition of neutralizing anti-hlL-6 an- 
tibodies (Fig. 5 B),  indicating that the stimulatory activity 
produced by melanoma cell is secreted IL-6. The results of 
the B9 cell bioassay are consistent with the observation of 
Northern  blotting  analyses;  both  provided  evidence  that 
these five IL-6 resistant cell lines are positive for endogenous 
IL-6 production, and secrete this product into their micro- 
environment. These results are in agreement with those of 
Table II. Scatchard Analysis of  lL-6 Receptor in Human 
Melanoma Cell Lines* 
[3H]thymidine 
incorporation 
(5  ng/ml  IL-6):  kD  Receptor 
Cell line  (percent of controls)  (x  I0  -t~ M)  sites per cell 
CESS  3.55 +  0.39  2,211  +  105 
WM 35  30.1 +  1.4  5.67  ~  1.07  580 +  53 
WM 1341B  30.7  + 0.1  1.51  •  0.10  365  •  54 
WM 902B  29.2  •  0.6  2.26  •  0.14  382  •  82 
WM 983A  95.8  •  4.8  1.48 + 0.23  212  :t: 38 
WM 451  91.2  •  2.7  1.48 +  0.27  463  •  9 
SKMEL 28  94.0  •  5.6  2.86  •  0.72  415  •  103 
9-A6-1  89.6 •  5.4  2.34  +  0.00  755  •  93 
* Data are expressed  as mean and SE. The CESS cell line was used as a posi- 
tive control. 
o 
1.251 
;"~  , 
1.001 
0.75  ""e'~"-. 
WM35  ￿9 
0.501 
o.o  oi~  o14  ole 
~ 
"'..o  ￿9 
",.  ￿9 
'-.,.. 
WM 1341B  ￿9  "~"'@ 
0.0  0.2  0.4 
t  ￿9 
1,2  "'".,.  ￿9  "..,,.  ￿9 
0.9  """...,. 
￿9  "-...e 
0.8  "~,.,.. 
0.3  WM  902B 
11 
,e 
0.5  ￿9  ,~... 
~  gasA 
O..0  011  012 
'oi  ....  "  ...... 
2  ""  ￿9 
"..￿9 
￿9  .  ￿9 
"l,.,.. 
~t  451  " ". 
o.o  o23  o~e 
"e,  e t 
~.... 
0.0  0.2  0.4  0.0  0.6  1,0 
Bound IL-6 (fmol) 
Figure 3.  Scatchard plot analysis of [nsI]IL-6 binding to human 
melanoma cell lines. Representative data of Scatchard plot analysis 
from six human melanoma cell lines are shown. The three cell lines 
on the left are growth inhibited by IL-6, whereas the three on the 
fight are not growth inhibited by exposure to exogenous IL-6. See 
also Table II. 
Colombo et al. (7) who found that ~50-60%  of advanced- 
stage human melanomas produce IL-6 in vitro. 
Endogenous 11.,-6 Functions us an Autocrine Growth 
Stimulator for Melanoma Cells 
Since we have shown that IL-6 is a potential growth inhibitor 
in human melanoma cell lines that are derived from early- 
stage (metastatically incompetent) primary lesions, the ques- 
tion we next addressed was the possible function of endog- 
enous IL-6 in IL-6 resistant melanoma cell lines known to 
produce it. Initial in vitro analyses were undertaken by add- 
ing  specific neutralizing anti-IL-6 antibodies into  the ceil 
culture medium. This did not result in any changes in [3H]- 
thymidine uptake in melanoma cells having endogenous IL-6 
Figure 4. Northern blot analysis of IL-6 gene expression of human 
melanoma cell  lines.  6  /~g of poly(A) + RNA preparation  from 
each cell line was used in each lane. Human IL-6 and GAPDH mes- 
sages are both below 18S. 
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Figure 5. Stimulating  activities  on 139 cell proliferation  by CM from 
human melanoma cell lines￿9 (A) Serum-free CM2 from 11 human 
melanoma cell lines was assayed on B9 cells, Data are expressed 
by mean (+SE) of two separate experiments conducted in triplicate 
determination. (B) Addition  of  anti-hlL-6 neutralizing antibody (10 
izg/ml) was found to abrogate the stimulatory activity  of either IL-6 
(25 pg) or CM2 from melanoma cell lines for B9 cells. 
production (Fig. 6). Failure of neutralizing  antibodies to al- 
ter the growth in vitro, however, does not exclude the possible 
intracellular action of  endogenous IL-6 in these cells, as pre- 
viously described in other systems such as multiple myeloma 
(29). Antisense oligonucleotide to human IL-6 gene has been 
successfully used by others to down-regulate  IL-6 produc- 
tion,  a procedure that  inhibited  cell proliferation  (29, 34). 
Therefore, we added a 15-mer antisense and a control sense 
oligonucleotide to human melanoma cell cultures.  After 2 d 
incubation,  addition  of the antisense oligonucleotide into 
culture medium resulted in a significant  inhibition  in pH]- 
thymidine incorporation  in WM9 human  melanoma  cells 
compared to the control (sense) oligonucleotide (Fig. 7 A). 
A  similar relative dose-dependent inhibition  of [~I-I]thymi- 
dine uptake was observed in both WM793 and MeWo cell 
lines (data not shown). When cell number was assessed, 10 
/zM of  oligonucleotide preparations were used in culture me- 
dium for 5 d. As shown in Fig. 7 B, cell proliferation  was 
t~gure 6.  bAdition of anti-IL-6 neutralizing antibody into culture 
medium does not affect the growth of melanoma cell lines that pro- 
duce  endogenous IL-6.  Human  melanoma cells (5  ￿  10Vwell) 
were cultured in 96-well plates for 2 d with or without IL-6 neutral- 
izing antibody (10 t~g/well). Human recombinant IL-6 (12.5 ng/ml) 
alone, or with IL-6 Ab, was added to WM35 and WM902B cell 
culture to show that the IL-tAb is biologically active. 
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Figure 7. Effect of IL-6 antisense oligonucleotides to IL-6 on the 
growth of  human melanoma cells. (A) WM9 human melanoma cells 
were plated in 96-well plates and incubated with different concen- 
trations of sense (dotted line) and antisense (solid line) phosphoro- 
thioate oligonueleotides  to the human IL-6 gene for 2 d. Cells were 
harvested 5  h  after pulse labeling with [3H]thymidine.  (B) Anti- 
sense oligonueleotide (15-mer) preparation was added into culture 
medium 00 t~M) and cell numbers were counted 5 d at~r. Cell num- 
bers in controls without addition of antisense oligonucleotide were 
considered as 100%. Similar results were obtained in a separate ex- 
periment. Data are expressed by mean (+ SE) from a representa- 
tive experiment. 
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lines. These results suggest a possible intracellular ("private") 
autocrine action of growth stimulation by IL-6 in human 
melanoma cells which produce this cytokine, similar to hu- 
man multiple myeloma (29), although further studies are re- 
quired to verify this possibility. The failure to achieve total 
inhibition of cell growth may be related to incomplete inhi- 
bition of the antisense oligonucleotide or to the production 
of additional autocrine growth factors by human melanoma 
cells such as bFGF and melanocyte growth stimulating activ- 
ity, i.e., MGSA (26). 
Discussion 
In recent studies we found a selective growth inhibition of 
human melanoma cell lines that were derived from patients 
with early-stage benign (curable) lesions, whereas all seven 
cell lines obtained from advanced-stage (metastatically com- 
petent) lesions were resistant to IL-6 growth inhibition (30). 
The results of the present studies do not support the notion 
that differential [t2sI]IL-6 binding to its receptors between 
IL-6-sensitive and resistant cell lines as being the mechanism 
mediating the selective inhibition. Northern blotting analysis 
also revealed similar mRNA levels for both IL-6 receptor and 
its associated IL-6 signal transducing protein, gpl30. Thus, 
although the mechanism of the resistant phenotype to IL-6 
induced growth inhibition in advanced-stage human mela- 
nomas remains to be clarified, in all likelihood it does not 
involve defective or altered cell surface IL-6 receptors. 
Endogenous IL-6 production was assessed by both North- 
ern blotting analysis and the B9 cell proliferation bioassay. 
Surprisingly, five out of eight melanoma cell lines known to 
be resistant to IL-6-mediated growth inhibition were found 
to be positive for endogenous  IL-6 production. This prompted 
us to ask whether this endogenous IL-6 had any function on 
melanoma cell growth. There are at least three possibilities: 
(a) IL-6 could still function as a growth inhibitor but in this 
case the melanoma cells are sufficiently  tolerant to overcome 
the inhibition; a precedent for this is found in TGF-/3 in which 
we previously showed that a colon carcinoma cell line was 
growth stimulated in vivo when transfected with an antisense 
TGF-fll expression vector (61); (b) it may be inert function- 
ally as found in three other IL-6 resistant cell lines, which 
are negative for endogenous IL-6 production; or (c) it may 
act as a growth stimulator by an autocrine mechanism as has 
been found in some hematologic cancers (24,  34,  29, 40, 
65). To analyze this problem, we added neutralizing antibod- 
ies to IL-6 into cell culture medium but this failed to alter 
the in vitro growth of melanoma cell lines endogenously 
positive for IL-6 production. However, the consistent growth 
inhibition we detected by addition of antisense oligonucleo- 
tides to the IL-6 gene into cell culture medium clearly indi- 
cated that endogenous IL-6 functions as a growth stimulator 
in these human melanoma cell lines, in all likelihood at an 
intracellular level. More recently we have found that trans- 
fection of  an IL-6 antisense expression vector into IL-6 posi- 
tive WM9 and MeWo melanoma cell lines significantly re- 
duced their  growth  in  nude mice  (our own unpublished 
observations). Thus, when taken together with previous ob- 
servations (30, 49) our results strongly suggest that IL-6 acts 
as a "bifunctional" cytokine for human melanoma cells dur- 
ing malignant tumor progression: it acts as a growth inhibi- 
tor for normal melanocyte (49) and for early-stage primary 
melanomas by a  paracrine  mechanism (30)  whereas  the 
more advanced-stage form of this malignancy has a distinct 
tendency to become resistant to IL-6 induced growth inhibi- 
tion-and in some cases to use it endogenously as a means 
of stimulating their own growth. Tumor cell-associated IL-6 
could also affect tumor growth in vivo by additional mecha- 
nisms, for example by influencing tumor angiogenesis (37) 
and/or by affecting the ability of  the immune system to recog- 
nize and destroy (immunogenic) tumor cells (41). 
Acquisition of endogenous IL-6 production and its possi- 
ble contribution in autocrine cell growth have been impli- 
cated as a key step in certain types of hematologic malignant 
tumor progression (21,  24,  29,  40,  65).  However,  the ef- 
fects and function of IL-6 in human malignancies of non- 
hematopietic origin would appear to be more complicated. 
For example, endogenous expression of IL-6 has been found 
in  prostate  and ovarian carcinoma cells  as  well as  glio- 
blastoma cells with no indication as yet about its function on 
the growth or other properties of these cancers (47, 56, 60). 
Growth inhibition or  stimulation mediated by IL-6 were 
reported for human breast carcinoma (5, 39) and renal cell 
carcinoma,  respectively  (33,  52).  Moreover,  in  a  recent 
study, no significant effect of human IL-6 on the in vitro 
growth of more than 26 human malignant nonhematopoietic 
cell lines, including two cell lines of breast carcinoma was 
observed  (46).  Since the latter study involved the use of 
advanced-stage malignant tumors, exogenous IL-6 might not 
be expected to have an effect, consistent with our melanoma 
results. However, many of these tumors may be inhibited by 
IL-6 in an earlier stage of  tumor progression, and conversely, 
may be stimulated "cryptically" in more advanced stages by 
endogenously  produced IL-6. Of possible significance in this 
regard, Sehgal and his associates have reported that the wild- 
type p53 suppressor gene may normally suppress IL-6 gene 
expression in epithelial cells (43). Hence, inactivation of the 
p53 gene by deletion and/or mutation may lead to ectopic 
production of IL-6 in carcinomas and other types of tumors 
which undergo such genetic alterations. This may help ex- 
plain the high frequency of IL-6 production in vitro (see 
above) or in vivo (43, 50) by solid tumors, since p53 gene 
mutations are found in as many as 50% or more of  all cancers 
(12). While our results have concentrated on IL-6 as a possi- 
ble hemopoietic autocrine growth factor in nonhematologic 
malignancies, it should be noted that other types of hemo- 
poietic growth factors have been implicated as possible au- 
tocrine  stimulators  of certain  carcinomas.  For  example, 
CSF-1 has been implicated to function in such a manner in 
both human breast and ovarian cancers (22, 23, 53). 
Progressive resistance or 'emancipation' (28) to the action 
of inhibitory growth factors during tumor progression has 
been noted in the context of other growth factors, especially 
TGF-fl (20, 31, 32, 36, 44, 54, 63) as reviewed recently by 
Kerbel (26).  Furthermore, in some cases paracrine TGF-fl 
has been shown to change from acting as an inhibitor to a 
growth stimulator during transition from low grade to well 
differentiated high grade advanced malignant cancers (19, 
20, 44, 63). However, to our knowledge, there is no prece- 
dent for a growth factor functioning as a potential paracrine 
growth inhibitor during one stage of tumor progression, and 
as an autocrine growth stimulator at a later, more malignant 
stage, as shown in this report. Such transitions in responsive- 
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cally competent) tumor ceils to grow progressively  at the 
primary tumor site,  i.e., to manifest a "growth dominant" 
phenotype (25), as well as to grow in distant organ sites. Our 
results  have  two  other important potential  implications. 
First,  they imply that IL-6-and by implication  perhaps 
other members of the hematopoietic growth factor family- 
may contribute to the growth of solid tumors in a more sig- 
nificant way than previously suspected.  Second, they raise 
the  intriguing  possibility  of  "multi-cytokine  resistance" 
(e.g., to TGF-fl and IL-6) and multi-growth factor indepen- 
dence (11) being important aspects of  the growth of advanced 
stage, metastatic,  cancers (26). 
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